Search

Displaying results 1271 - 1280 of 2256 in total
  1. Target

    Leukocyte immunoglobulin-like receptor subfamily B member 2

    go.drugbank.com/bio_entities/BE0010561
    TargetHumans

    Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles (PubMed:11169396, PubMed:12853576, PubMed:16455647, PubMed:20448110, PubMed:27859042).

    Polypeptides: Leukocyte immunoglobulin-like receptor subfamily B member 2Synonyms: Leukocyte immunoglobulin-like receptor 2, Monocyte/macrophage immunoglobulin-like receptor 10
  2. Target

    Leukocyte immunoglobulin-like receptor subfamily B member 1

    go.drugbank.com/bio_entities/BE0010562
    TargetHumans

    Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles (PubMed:16455647, PubMed:28636952). … Receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response.

    Polypeptides: Leukocyte immunoglobulin-like receptor subfamily B member 1Synonyms: Leukocyte immunoglobulin-like receptor 1, Monocyte/macrophage immunoglobulin-like receptor 7
  3. Target

    Leukocyte immunoglobulin-like receptor subfamily B member 4

    go.drugbank.com/bio_entities/BE0017129
    TargetHumans

    This inhibition of monocyte activation occurs at least in part via binding to FN1 (PubMed:34089617). … Receptor for apolipoprotein APOE (PubMed:30333625). Receptor for ALCAM/CD166 (PubMed:29263213).

    Polypeptides: Leukocyte immunoglobulin-like receptor subfamily B member 4Synonyms: Monocyte inhibitory receptor HM18, Leukocyte immunoglobulin-like receptor 5
  4. Target

    Mas-related G protein-coupled receptor member X2

    go.drugbank.com/bio_entities/BE0018408
    TargetHumans

    Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase (PubMed … Mast cell-specific G protein-coupled receptor for basic secretagogues, which regulates mast cell degranulation and itch-related hypersensitivity reactions (PubMed:22069323, PubMed:25517090, PubMed:28288109

    Polypeptides: Mas-related G protein-coupled receptor member X2Function: C-C chemokine receptor activity
  5. Drug

    Hexylresorcinol

    go.drugbank.com/drugs/DB11254
    Approved

    Hexylresorcinol is a substituted dihydroxybenzene. It exhibits antiseptic, anthelmintic, and local anesthetic properties. It can be found in topical applications for minor skin infections and in oral solutions or throat lozenges for pain...

  6. Drug

    Tegaserod

    go.drugbank.com/drugs/DB01079
    ApprovedWithdrawn

    [L5918,F4229] It was, however, voluntarily withdrawn from widespread use in the US market in 2007 after concerns arose over the possibility that tegaserod could potentially cause dangerous cardiovascular … [F4226] Despite the relative complications involved in its history of regulatory approval, ever since its first introduction in 2002 tegaserod remains the only therapy for IBS-C that possesses the unique

    Categories: Serotonin-4 Receptor Agonist, Serotonin 4 Receptor Agonists
  7. Drug

    Tisotumab vedotin

    go.drugbank.com/drugs/DB16732
    ApprovedInvestigational

    a tissue factor-directed antibody-drug conjugate (ADC) comprised of an anti-tissue factor (TF) human IgG1-kappa antibody conjugated to monomethyl auristatin E (MMAE), a microtubule-disrupting agent, via

  8. Drug

    Vosoritide

    go.drugbank.com/drugs/DB11928
    ApprovedInvestigational

    Endogenous CNP, first described in 1998, is primarily responsible for the stimulation of chondrocytes and long bone growth via activity at the NPR-B receptor, making it an attractive target in the treatment

  9. Drug

    Rosiglitazone

    go.drugbank.com/drugs/DB00412
    ApprovedInvestigational

    Recent research has suggested that rosiglitazone may also be of benefit to a subset of patients with Alzheimer's disease not expressing the ApoE4 allele. … Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ

    Categories: Peroxisome Proliferator Receptor gamma Agonist, Peroxisome Proliferator-activated Receptor Activity
  10. Indication

    Triple-Negative Breast Cancer

    go.drugbank.com/conditions/DBCOND0068542
    Drugs: Atezolizumab
    Synonyms: Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative